Evidence map›Paper›PMID 36687433›Full record

ArticleFrontiers in medicine2022

Whole-genome sequencing of SARS-CoV-2 isolates from symptomatic and asymptomatic individuals in Tanzania.

Shabani Ramadhani Mziray, Marco van Zwetselaar, Charles C Kayuki, Peter M Mbelele, Abel N Makubi, Alex S Magesa, Riziki M Kisonga, Tolbert B Sonda, Gibson S Kibiki, George Githinji and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Shabani Ramadhani MzirayDepartment of Biochemistry and Molecular Biology, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Marco van ZwetselaarKilimanjaro Clinical Research Institute, Moshi, Tanzania.
Charles C KayukiOxford Nanopore Technologies, Oxford, United Kingdom.
Peter M MbeleleKibong'oto Infectious Diseases Hospital, Sanya Juu, Tanzania.
Abel N MakubiMinistry of Health, Dodoma, Tanzania.
Alex S MagesaMinistry of Health, Dodoma, Tanzania.
Riziki M KisongaKibong'oto Infectious Diseases Hospital, Sanya Juu, Tanzania.
Tolbert B SondaKilimanjaro Clinical Research Institute, Moshi, Tanzania.
Gibson S KibikiThe Africa Research Excellence Fund (AREF), London, United Kingdom.
George GithinjiKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Scott K HeysellDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, United States.
Jaffu O ChilongolaDepartment of Biochemistry and Molecular Biology, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Stellah G MpagamaKibong'oto Infectious Diseases Hospital, Sanya Juu, Tanzania.
Kilimanjaro Christian Medical Centre · TZMinistry of Health, Community Development, Gender, Elderly and Children · TZKenya Medical Research Institute · KEOxford Nanopore Technologies (United Kingdom) · GBUniversity of Virginia · US

Funding

A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan AfricaU01AI150508 · NIAID · UNIVERSITY OF VIRGINIA · PI HEYSELL, SCOTT K, MOORE, CHRISTOPHER CHARLES · 2020 to 2024
$3.3M
NIAID NIH HHS U01 AI150508
6 · The paper itself

Abstract

Background: Coronavirus Disease-2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) accounts for considerable morbidity and mortality globally. Paucity of SARS-CoV-2 genetic data from Tanzania challenges in-country tracking of the pandemic. We sequenced SARS-CoV-2 isolated in the country to determine circulating strains, mutations and phylogenies and finally enrich international genetic databases especially with sequences from Africa. Methods: This cross-sectional study utilized nasopharyngeal swabs of symptomatic and asymptomatic adults with positive polymerase chain reaction tests for COVID-19 from January to May 2021. Viral genomic libraries were prepared using ARTIC nCoV-2019 sequencing protocol version three. Whole-genome sequencing (WGS) was performed using Oxford Nanopore Technologies MinION device. Results: Twenty-nine (42%) out of 69 samples qualified for sequencing based on gel electrophoretic band intensity of multiplex PCR amplicons. Out of 29 isolates, 26 were variants of concern [Beta ( Conclusion: We provide evidence of existence of Beta, Delta, Eta variants and a locally evolving lineage (B.1.530) from samples collected in early 2021 in Tanzania. This work provides a model for ongoing WGS surveillance that will be required to inform on emerging and circulating SARS-CoV-2 diversity in Tanzania and East Africa.

Indexed as

COVID-19MinIONOxford Nanopore Technologies (ONT)SARS-CoV-2variant of interestvariants of concernwhole-genome sequencing

Identifiers

PMID36687433
PMCPMC9846855
OpenAlexW4313492798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.